Clinical efficacy and safety evaluation of New Tiaoxin Decoction in the treatment of Mild Cognitive Impairment

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000035938

Enrollment

Unknown

Registered

2020-08-20

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive Impairment

Interventions

1:New Tiaoxin Decoction

2:donepezil

Eligibility

Sex/Gender

All

Age

50 Years to No maximum

Inclusion criteria

Inclusion criteria: reference resource Guidelines for clinical research of Mild Cognitive Impairment (Draft) (2008 Edition)

Exclusion criteria

Exclusion criteria: reference resource Guidelines for clinical research of mild cognitive impairment (Draft) (2008 Edition)

Design outcomes

Primary

Measure	Time frame
mini-mental state examination,MMSE;Montreal cognitive assessment,MoCA;	—

Secondary

Measure	Time frame
Alzheimer disease assessment scale-cog, ADAS-cog;Wechsler memory scale-Revised, WMS-R;Activities of Daily Living, ADL;The Neuropsychiatric Inventory, NPI;	—

Countries

China

Contacts

Public ContactDanfei Lou

Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine

xinye922@163.com+86 13402136316

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026